IDEAYA reports 57% eye preservation with darovasertib

• IDEAYA Biosciences reported a 57% eye preservation rate among primary uveal melanoma patients initially recommended for eye removal in its OptimUM-09 trial.
• In OptimUM-01, darovasertib plus crizotinib achieved 7.4 months of median progression-free survival and 27.1 months of median overall survival in 13 previously untreated patients.
• IDEAYA plans to present updated findings at ESMO 2026 and complete its U.S. regulatory submission for darovasertib plus crizotinib in the second half of 2026.

IDEAYA Biosciences (NASDAQ:IDYA) reported a 57% eye preservation rate in its OptimUM-09 trial, alongside updated darovasertib findings from two metastatic uveal melanoma studies.

The OptimUM-01 combination achieved 7.4 months of median progression-free survival and 27.1 months of median overall survival among 13 previously untreated patients.

“These three clinical updates at ESMO continue to support our belief in the potential for darovasertib to address important unmet needs across the uveal melanoma treatment journey,” said IDEAYA Biosciences Chief Executive Officer Yujiro S. Hata.

OptimUM-09 showed reduced planned radiation doses in 66% of its radiation cohort, while 8.9% of OptimUM-01 participants discontinued treatment because of related adverse events.

IDEAYA plans to present updated June 15 findings at ESMO on October 24 and complete its regulatory submission in 2026.

OptimUM-02 previously demonstrated median progression-free survival of 6.9 months against 3.1 months with investigator-selected therapy, with updated subgroup analyses supporting the earlier findings.

IDEAYA partnered with Servier in 2025 to develop darovasertib internationally, while maintaining U.S. rights and pursuing additional targeted cancer therapies.